SER — Serina Therapeutics, Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1708599 ·
Last close
$1.37
Market Cap
$36.27M
52W High
$4.26
52W Low
$1.14
ADV30
61,978
Next earnings
—
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 0 — -6,784,000 -6,356,000 25,814,000 23,024,000 7,084,000
Mar 2026 0 — -6,280,000 -6,898,000 27,299,000 24,526,000 9,671,000
Dec 2025 0 — -6,207,000 -3,336,000 6,951,000 3,056,000 6,988,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-21,135,000
Investing CF
$-66,000
Financing CF
$38,184,000
CapEx
$-66,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.24
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-76,754,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-20,564,000
Pretax Income TTM
$-21,160,000
Interest Exp TTM
$596,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-25,587,000
Free Cash Flow
$-12,350,875
Enterprise Value
$16,544,667
Total Cash
$23,024,000
Total Debt
$3,754,000
Shares Out
26,569,458
Trailing EPS
$-1.63
Book Value
$-0.46
ROE
-207.9%
ROA
-92.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -24,022,000 -19,182,000 6,951,000 6,988,000 -37,000 -17,955,000
Dec 2024 0 -17,048,000 -11,141,000 6,724,000 6,216,000 641,000 -17,137,000
Dec 2023 3,000,000 -3,129,000 5,269,000 8,968,000 41,262,000 -32,294,000 -2,476,000
Dec 2022 500,000 -2,270,368 -2,682,108 858,042 38,636,203 -37,778,161 -2,075,624

TTM Snapshot

Revenues TTM
—
NetIncome TTM
$-21,175,000
OpCashFlow TTM
—
Assets (Latest)
$25,814,000
Forward EPS
$-1.05

Peers — same industry

TickerNameMarket CapLastDaily %
GRCE Grace Therapeutics, Inc. $36.18M $1.72 —
CNTB Connect Biopharma Holdings Ltd $36.45M $0.58 —
VERU VERU INC. $36.49M $2.14 —
BMEA Biomea Fusion, Inc. $35.47M $0.49 —
OSTX OS Therapies Inc $34.86M $0.74 —

News headlines (Yahoo Finance, 1h cache)

Serina Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-12 21:20 · Yahoo
Epigenetic Reprogramming Longevity Therapeutics Global Market Report 2026 | Capture $16.14B AI and Cell Reprogramming Growth as Retro Biosciences, Altos Labs and NewLimit Lead
2026-10-30 14:41 · Yahoo
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
2026-09-23 20:18 · Yahoo
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 20:05 · Yahoo
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
2026-09-09 11:45 · Yahoo
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-13 20:15 · Yahoo
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
2026-07-23 10:00 · Yahoo
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
2026-07-22 20:30 · Yahoo
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
2026-06-30 13:01 · Yahoo
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
2026-04-07 10:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.